Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)

NCT00577824 · Completed

Last updated 2026-05-28

This clinical trial tested the effects of the medication exenatide in Japanese adults with type 2 diabetes who were already taking oral diabetes medications.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 181 people

Who can join Ages 20–75 · all sexes

Timeline Started 2008-01 · est. completion 2008-11

Where 12 sites · Japan

What this study is testing ClinicalTrials.gov NCT00577824 ↗

Description as written by the study sponsor.

This long term, placebo-controlled trial is intended to assess the efficacy and safety of exenatide, dosed twice a day, in Japanese patients with Type 2 Diabetes who are treated with oral antidiabetic(s) but not well controlled.

Treatments tested

exenatide also known as LY2148568, Byetta Drug

subcutaneous injection, 5mcg, twice a day
exenatide also known as LY2148568, Byetta Drug

subcutaneous injection, 10mcg, twice a day
placebo Drug

subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day

Main thing measured	Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00577824 ↗